MPO high | MPO low | p-value | |
---|---|---|---|
n = 12 (100 %) | n = 35 (100 %) | ||
Age (median, range) | 55 (45–73) | 60 (34–77) | 0.196 |
FIGO stage | |||
II | 0 | 1 (2.9) | 0.401 |
IIIA | 0 | 1 (2.9) | |
IIIB | 3 (25.0) | 2 (5.7) | |
IIIC | 7 (58.3) | 25 (71.4) | |
IV | 2 (16.7) | 6 (17.1) | |
Residual disease | |||
None | 4 (33.3) | 12 (34.3) | 0.919 |
<2 cm | 5 (41.7) | 12 (34.3) | |
>2 cm | 3 (25.0) | 10 (28.6) | |
Numbers of chemotherapy cycles | |||
<6 | 1 (8.3) | 6 (17.1) | 0.440 |
6 or more | 11 (91.7) | 28 (80.0) | |
Primary cancer biopsies | |||
CSb | 10 (83.3) | 23 (65.7) | 0.249 |
CRb | 2 (16.7) | 12 (34.3) | |
Recurrent cancer biopsies (n = 10/35) | |||
CSb | 9 (90.0) | 23 (65.7) | 0.135 |
CRb | 1 (10.0) | 12 (34.3) | |
RFSc (mean/SE) | 11.9 (2.7) | 9.5 (1.6) | 0.380 |
OSc (mean/SE) | 56.8 (14.4) | 39.3 (4.4) | 0.139 |